Navigation Links
New advances in cancer research to be highlighted at University of Leicester
Date:4/21/2009

A scientist whose work is key to understanding how cancer cells divide and spread in the body is to present advances in his latest research at a public forum to be held at the University of Leicester.

Professor Andrew Fry, of the Department of Biochemistry, leads a renowned research group at the University of Leicester that is internationally consulted as a leading laboratory in the field of Molecular Cell Biology.

Many current cancer treatments act by killing all dividing cells and are not necessarily specific for the cancer cells, hence the severe side effects. One of Professor Fry's aims is to understand the molecular control of cell division and as a result identify proteins which can be targeted in specific tumours, leaving other cells unharmed.

On Tuesday April 28, Professor Fry will discuss his research and its future direction. The lecture, How Cells Control the Great Divide, in the Ken Edwards Building Lecture Theatre 1, starts at 5.30pm. It is open to the public and free.

Professor Fry said: "In my presentation, I will highlight how our research has contributed to the understanding of a key aspect of human cell biology that is cell division. This research has provided important new insights on the causes of many human diseases, including cancer, and led to the identification of a number of new targets for cancer treatment.

"An adult human being contains millions of cells that all arise following the fertilization of an egg cell by a sperm cell. Human development therefore requires cells to divide again and again to create the tissues and organs of our body. Cell division is a complex mechanical process that not only leads to the production of new cells but ensures that each one maintains the right genetic content required to sustain life. Loss of control over cell proliferation and the development of genetic and chromosomal abnormalities are classic hallmarks of cancer."

Professor Fry added that the group's research falls into three broad areas:

  • Study of a family of proteins that play a role in cell division and cilia organization which makes them attractive targets for the development of new anti-cancer drugs

  • Research on a particular structure that lies at the heart of each and every cell, called the centrosome (standing for "central body"), and how centrosome defects contribute to cancer progression

  • Examination of the cell biological basis of ciliopathy disorders, a diverse set of devastating human diseases with symptoms ranging from polycystic kidney disease to mental retardation, obesity and progressive blindness.

"Something that has helped us to establish a world-class reputation is a state-of-the-art Microscopy facility at the University of Leicester. The ability to use high resolution microscopy, to see what is actually going on in cells, is critical to research. So having this facility at Leicester allows us to compete at world level."


'/>"/>

Contact: Professor Andrew Fry
amf5@le.ac.uk
44-116-229-7069
University of Leicester
Source:Eurekalert

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
3. Major grant advances UWs clinical and translational research enterprise
4. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
5. Innovation and Medical Advances to be Highlighted on Final Day of Inaugural AdvaMed 2007 Conference
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Advances in drug screening: building a better haystack for the needles of tomorrow
8. Advances in Cancer Research, Funding Stem Cell Research, and More at Annual Cancer Congress
9. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
10. Springer adds Advances in Therapy to journals portfolio
11. NIH grant advances dentistry schools work on psychosocial stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The ... consultations to communities in the greater Denver region, is announcing a charity drive ... a very rare kind of epilepsy. , Until a few months ago, Dominik ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen ... services to communities in the greater Birmingham area, is joining the Chris Hammond ... young people in the region. , The Chris Hammond Youth Foundation maintains athletic ...
(Date:7/21/2017)... PHILADELPHIA (PRWEB) , ... July 21, 2017 , ... ... ARTZ Philadelphia and Theater of Witness , was awarded a $300,000 ... growing humanities program which fosters empathy, comfort with ambiguity and the recognition of ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” ... plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... medical students improve their chances of acceptance to a residency in a United ... have earned degrees outside the U.S. , According to data released by the ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... Md. , July 13, 2017  New York City-based ... of pharmaceutical markets should be aware of.  From new products ... trends are detailed in a recently completed study, Potential ... 1.  Age-Driven Growth ... we have been aware of the impact the growing population ...
(Date:7/11/2017)...  Bayer has awarded grants totaling more than $2 million ... prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and ... and Uniformed Services University of the Health Sciences in ... recipients were announced last night during a reception at the ... Berlin, Germany . ...
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
Breaking Medicine Technology: